Bafrekalant
Bafrekalant is a diazabicyclic substituted imidazo[l,2-a]pyrimidine-derivative. Bafrekalant has the potential for the research of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring (extracted from patent WO2018228907A1) .
Product Specifications
CAS Number
2256770-44-0
UNSPSC
12352005
Target
Drug Derivative
Type
Reference compound
Related Pathways
Others
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/bafrekalant.html
Concentration
10mM
Purity
99.67
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
CC(C1=CC=C(C=C1)C2=C(N(C=CC=N3)C3=N2)CN(CC4CC5)CC5N4C(C(N=C6OC)=C(C=C6)Cl)=O)C
Molecular Formula
C29H31ClN6O2
Molecular Weight
531.05
References & Citations
[1]Martina Delbeck, et al. Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders. Patent WO2018228907A1.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Angiotensin I Converting Enzyme (ACE) / CD143 (9B9), CF594 conjugate, 0.1mg/mL
